Zuclopenthixol (BioDeep_00000017957)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol

化学式: C22H25ClN2OS (400.137603)
中文名称: 氯哌噻吨, 珠氯噻醇
谱图信息: 最多检出来源 Homo sapiens(blood) 5%

分子结构信息

SMILES: C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
InChI: InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-

描述信息

Zuclopenthixol is only found in individuals that have used or taken this drug. It is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. [PubChem]Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene group. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AF - Thioxanthene derivatives
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
Zuclopenthixol ((Z)-Clopenthixol) is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist[1][2].

同义名列表

14 个代谢物同义名

2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; Zuclopenthixol dihydrochloride; Zuclopenthixol decanoate; Zuclopenthixol acetate; alpha-Clopenthixol; alpha Clopenthixol; Zuclopenthixolum; Zuclopenthixol; Zuclopentixol; CLOPENTHIXOL; Cisordinol; Clopixol; (Z)-Clopenthixol



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ragnhild Birkeland Waade, Vigdis Solhaug, Gudrun Høiseth. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. British journal of clinical pharmacology. 2021 05; 87(5):2228-2235. doi: 10.1111/bcp.14626. [PMID: 33118660]
  • Marit Tveito, Robert Løvsletten Smith, Espen Molden, Gudrun Høiseth. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. European journal of clinical pharmacology. 2021 Feb; 77(2):215-221. doi: 10.1007/s00228-020-03002-y. [PMID: 33000414]
  • Virginie Bulot, Cédric Lemogne, Nicaise Nebot, Hugues Blondon, Paul Roux. Systematic prevention of severe constipation induced by antipsychotic agents: A quasi-experimental study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016 10; 26(10):1690-1. doi: 10.1016/j.euroneuro.2016.08.004. [PMID: 27546374]
  • Patteet Lisbeth, Haufroid Vincent, Maudens Kristof, Sabbe Bernard, Morrens Manuel, Neels Hugo. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. European journal of clinical pharmacology. 2016 Feb; 72(2):175-84. doi: 10.1007/s00228-015-1965-1. [PMID: 26514968]
  • Kristina Melkersson, Moira Lewitt, Kerstin Hall. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro endocrinology letters. 2015; 36(5):465-80. doi: NULL. [PMID: 26707048]
  • Guillaume Fond, Alexandra MacGregor, Deborah Ducasse, Marie Brittner. Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. Psychiatry research. 2014 May; 216(2):286-7. doi: 10.1016/j.psychres.2014.01.049. [PMID: 24582773]
  • V Schwarz, O Reis, T Glaser, J Thome, C Hiemke, F Haessler. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Pharmacopsychiatry. 2014 Jan; 47(1):29-32. doi: 10.1055/s-0033-1361115. [PMID: 24307207]
  • John J Sheehan, Kristin R Reilly, Dong-Jing Fu, Larry Alphs. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innovations in clinical neuroscience. 2012 Jul; 9(7-8):17-23. doi: NULL. [PMID: 22984648]
  • Katharina Wulff, Derk-Jan Dijk, Benita Middleton, Russell G Foster, Eileen M Joyce. Sleep and circadian rhythm disruption in schizophrenia. The British journal of psychiatry : the journal of mental science. 2012 Apr; 200(4):308-16. doi: 10.1192/bjp.bp.111.096321. [PMID: 22194182]
  • S J C Davies, A A Westin, I Castberg, G Lewis, M S Lennard, S Taylor, O Spigset. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta psychiatrica Scandinavica. 2010 Dec; 122(6):444-53. doi: 10.1111/j.1600-0447.2010.01619.x. [PMID: 20946203]
  • Asuman Orhan Varoglu, Orhan Ates, Omer Lutfi Gundogdu, Asude Aksoy, Orhan Deniz. Zuclopenthixol-induced neuroleptic malignant syndrome presenting as fever of unknown origin, hyperglycaemia and acute myocardial infarction in a 60-year-old man. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2009; 10(4 Pt 2):644-7. doi: 10.1080/15622970701714347. [PMID: 17965986]
  • Ingrid Castberg, Olav Spigset. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Therapeutic drug monitoring. 2008 Oct; 30(5):597-603. doi: 10.1097/ftd.0b013e31818622c4. [PMID: 18708990]
  • Lars H Pinborg, Charlotte Videbaek, Morten Ziebell, Torben Mackeprang, Lars Friberg, Hans Rasmussen, Gitte M Knudsen, Birte Y Glenthoj. [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. NeuroImage. 2007 Feb; 34(4):1450-3. doi: 10.1016/j.neuroimage.2006.11.003. [PMID: 17175177]
  • Pierre Chue. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric disease and treatment. 2007 Feb; 3(1):13-39. doi: 10.2147/nedt.2007.3.1.13. [PMID: 19300536]
  • H Kirchherr, W N Kühn-Velten. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Oct; 843(1):100-13. doi: 10.1016/j.jchromb.2006.05.031. [PMID: 16798119]
  • Gabriel Rubio, Isabel Martínez, Guillermo Ponce, Miguel Angel Jiménez-Arriero, Francisco López-Muñoz, Cecilio Alamo. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2006 Jul; 51(8):531-9. doi: 10.1177/070674370605100808. [PMID: 16933590]
  • Frank M C Besag, David Berry. Interactions between antiepileptic and antipsychotic drugs. Drug safety. 2006; 29(2):95-118. doi: 10.2165/00002018-200629020-00001. [PMID: 16454538]
  • Peter Herriot, Kamran Kheirani. Survey of depot antipsychotic prescribing in southern Adelaide. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. 2005 Sep; 13(3):253-7. doi: 10.1080/j.1440-1665.2005.02196.x. [PMID: 16174198]
  • Guido Mannaioni, Roberto Baronti, Flavio Moroni. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Therapeutics and clinical risk management. 2005 Sep; 1(3):225-30. doi: NULL. [PMID: 18360563]
  • G Dumortier, B Welniarz, C Sauvebois, H Medjdoub, H Friche, N Siad, K Degrassat. [Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives]. L'Encephale. 2005 Jul; 31(4 Pt 1):477-89. doi: 10.1016/s0013-7006(05)82409-1. [PMID: 16389715]
  • Ursula Gutteck, Katharina M Rentsch. Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clinical chemistry and laboratory medicine. 2003 Dec; 41(12):1571-9. doi: 10.1515/cclm.2003.240. [PMID: 14708881]
  • L Garay Garcia, I Forfar-Bares, F Pehourcq, C Jarry. Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography. Application to management of acute intoxications. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Oct; 795(2):257-64. doi: 10.1016/s1570-0232(03)00576-2. [PMID: 14522030]
  • Vincenzo Pucci, Francesca Bugamelli, Roberto Mandrioli, Claudio Bartoletti, Nicola Rossi, Maria Augusta Raggi. Liquid chromatographic analysis of the cis(Z)- and trans(E)-isomers of clopenthixol in human plasma using a novel solid phase extraction procedure. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Jul; 792(2):313-21. doi: 10.1016/s1570-0232(03)00317-9. [PMID: 12860039]
  • Carsten Kratzsch, Frank T Peters, Thomas Kraemer, Armin A Weber, Hans H Maurer. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. Journal of mass spectrometry : JMS. 2003 Mar; 38(3):283-95. doi: 10.1002/jms.440. [PMID: 12644990]
  • Peeter Jaanson, Toomas Marandi, Raul-Allan Kiivet, Veiko Vasar, Siiri Vään, Jan-Olof Svensson, Marja-Liisa Dahl. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology. 2002 Jun; 162(1):67-73. doi: 10.1007/s00213-002-1059-5. [PMID: 12107620]
  • Marja-Liisa Dahl. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?. Clinical pharmacokinetics. 2002; 41(7):453-70. doi: 10.2165/00003088-200241070-00001. [PMID: 12083975]
  • F A Aly, S A al-Tamimi, A A Alwarthan. Flow-injection chemiluminometric determination of some thioxanthene derivatives in pharmaceutical formulations and biological fluids using the [Ru(dipy)3(2+)]-Ce(IV) system. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry. 2001 Nov; 17(11):1257-61. doi: 10.2116/analsci.17.1257. [PMID: 11759505]
  • H R Angelo, A Petersen. Therapeutic drug monitoring of haloperidol, perphenazine, and zuclopenthixol in serum by a fully automated sequential solid phase extraction followed by high-performance liquid chromatography. Therapeutic drug monitoring. 2001 Apr; 23(2):157-62. doi: 10.1097/00007691-200104000-00011. [PMID: 11294517]
  • R W Licht, M Bysted, H Christensen. Fixed-dosed risperidone in mania: an open experimental trial. International clinical psychopharmacology. 2001 Mar; 16(2):103-10. doi: 10.1097/00004850-200103000-00005. [PMID: 11236068]
  • M Read, N Caulkett, M McCallister. Evaluation of zuclopenthixol acetate to decrease handling stress in wapiti. Journal of wildlife diseases. 2000 Jul; 36(3):450-9. doi: 10.7589/0090-3558-36.3.450. [PMID: 10941729]
  • H Koers. [Priapism caused by simultaneous use of zuclopentixol and paroxetine]. Nederlands tijdschrift voor geneeskunde. 1999 Jan; 143(4):208-10. doi: NULL. [PMID: 10086144]
  • K Linnet, O Wiborg. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Therapeutic drug monitoring. 1996 Dec; 18(6):629-34. doi: 10.1097/00007691-199612000-00001. [PMID: 8946657]
  • M Jerling, M L Dahl, A Aberg-Wistedt, B Liljenberg, N E Landell, L Bertilsson, F Sjöqvist. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical pharmacology and therapeutics. 1996 Apr; 59(4):423-8. doi: 10.1016/s0009-9236(96)90111-3. [PMID: 8612387]
  • S Nyberg, L Farde, A Bartfai, C Halldin. Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. International clinical psychopharmacology. 1995 Nov; 10(4):221-7. doi: 10.1097/00004850-199511000-00003. [PMID: 8748043]
  • K Linnet. Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Therapeutic drug monitoring. 1995 Jun; 17(3):308-11. doi: . [PMID: 7624929]
  • M Kjølbye, K Thomsen, T Rogne, E Rehfelt, O V Olesen. Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients. Therapeutic drug monitoring. 1994 Dec; 16(6):541-7. doi: 10.1097/00007691-199412000-00002. [PMID: 7878691]
  • G Chouinard, G Safadi, L Beauclair. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Journal of clinical psychopharmacology. 1994 Dec; 14(6):377-84. doi: NULL. [PMID: 7884017]
  • B B Hansen, S H Hansen. Determination of zuclopenthixol and its main N-dealkylated metabolite in biological fluids using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. Journal of chromatography. B, Biomedical applications. 1994 Aug; 658(2):319-25. doi: 10.1016/0378-4347(94)00245-2. [PMID: 7820260]
  • T Solgaard, K Kistrup, T Aaes-Jørgensen, J Gerlach. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels. Pharmacopsychiatry. 1994 May; 27(3):119-23. doi: 10.1055/s-2007-1014290. [PMID: 8078952]
  • J H Poulsen, O V Olesen, N E Larsen. Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Therapeutic drug monitoring. 1994 Apr; 16(2):155-9. doi: 10.1097/00007691-199404000-00008. [PMID: 8009563]
  • H A Nygaard, K Bakke, E Brudvik, K Elgen, G K Lien. Dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour: a double-blind study with zuclopenthixol. Current medical research and opinion. 1994; 13(4):222-32. doi: 10.1185/03007999409110487. [PMID: 7882702]
  • K Thomsen, O V Olesen, J H Poulsen. [The effect of serum monitoring on concentration of perphenazine and zuclopenthixole]. Ugeskrift for laeger. 1993 Aug; 155(32):2443-8. doi: . [PMID: 8356762]
  • C H Tan, B L Low, L L Ng, Y M Khoo, H S Lee. Clinical evaluation and serum concentration of zuclopenthixol acetate in psychotic Asian patients: a single-dose preliminary study. Therapeutic drug monitoring. 1993 Apr; 15(2):108-12. doi: 10.1097/00007691-199304000-00007. [PMID: 8099240]
  • M Bloch, E Gur, A Y Shalev. Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance?. Psychopharmacology. 1992; 109(3):377-8. doi: 10.1007/bf02245887. [PMID: 1365639]
  • M L Dahl, B Ekqvist, J Widén, L Bertilsson. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta psychiatrica Scandinavica. 1991 Jul; 84(1):99-102. doi: 10.1111/j.1600-0447.1991.tb01428.x. [PMID: 1927573]
  • L P Balant, A E Balant-Gorgia, R Eisele, B Reith, M Gex-Fabry, G Garrone. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry. 1989 Nov; 22(6):250-4. doi: 10.1055/s-2007-1014609. [PMID: 2575763]
  • C J Kemperman, J H Gerdes, J De Rooij, L M Vencken. Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology. Journal of neurology, neurosurgery, and psychiatry. 1989 May; 52(5):679-80. doi: 10.1136/jnnp.52.5.679-a. [PMID: 2732745]
  • T Aaes-Jørgensen. Pharmacokinetics of three different injectable zuclopenthixol preparations. Progress in neuro-psychopharmacology & biological psychiatry. 1989; 13(1-2):77-85. doi: 10.1016/0278-5846(89)90005-5. [PMID: 2568662]
  • I Matheson, J Skjaeraasen. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients. European journal of clinical pharmacology. 1988; 35(2):217-20. doi: 10.1007/bf00609257. [PMID: 3191943]
  • A Viala, B Ba, A Durand, F Gouezo, N Hou, A Jørgensen. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology. 1988; 94(3):293-7. doi: 10.1007/bf00174677. [PMID: 2895936]
  • J C Levron, R Ropert. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. L'Encephale. 1987 Mar; 13(2):83-7. doi: . [PMID: 2885172]
  • T Aaes-Jørgensen, H Liedholm, A Melander. Influence of food intake on the bioavailability of zuclopenthixol. Drug-nutrient interactions. 1987; 5(3):157-60. doi: NULL. [PMID: 3691322]
  • A C Tas, J van der Greef, M C ten Noever de Brauw, T A Plomp, R A Maes, M Hohn, U Rapp. LC/MS determination of bromazepam, clopenthixol, and reserpine in serum of a non-fatal case of intoxication. Journal of analytical toxicology. 1986 Mar; 10(2):46-8. doi: 10.1093/jat/10.2.46. [PMID: 2871228]
  • T Aaes-Jørgensen, F Bjørndal, U Bartels. Zuclopenthixol levels in serum and breast milk. Psychopharmacology. 1986; 90(3):417-8. doi: 10.1007/bf00179202. [PMID: 2878463]
  • B Szukalski, B Lipska, L Welbel, K Nurowska. Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology. 1986; 89(4):428-31. doi: 10.1007/bf02412115. [PMID: 2875481]
  • A Amdisen, T Aaes-Jørgensen, N J Thomsen, V T Madsen, M S Nielsen. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology. 1986; 90(3):412-6. doi: 10.1007/bf00179201. [PMID: 2878462]
  • O Svendsen, L Blom, T Aaes-Jørgensen, J J Larsen. Local toxicity of different drugs after intramuscular or intralipomatous injection in pigs: serum concentrations after three different formulations of cis(Z)-clopenthixol. Acta pharmacologica et toxicologica. 1985 Aug; 57(2):78-87. doi: 10.1111/j.1600-0773.1985.tb00014.x. [PMID: 4061093]
  • M W Jann, L Ereshefsky, S R Saklad. Clinical pharmacokinetics of the depot antipsychotics. Clinical pharmacokinetics. 1985 Jul; 10(4):315-33. doi: 10.2165/00003088-198510040-00003. [PMID: 2864156]
  • A Jørgensen, T Aaes-Jørgensen, A Gravem, K F Amthor, S J Dencker, I Rosell, P C Baastrup, J Buckhave, L F Gram. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology. 1985; 87(3):364-7. doi: 10.1007/bf00432722. [PMID: 2867572]
  • A Viala, N Hou, B Ba, A Durand, H Dufour, N D'Agostino, C Berda, A Jørgensen. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology. 1984; 83(2):147-50. doi: 10.1007/bf00429723. [PMID: 6146995]
  • A Viala, N Hou, A Durand, B Ba, T Aaes-Jørgensen, A Jørgensen. [Determination of cis(Z)-clopenthixol and fluphenazine in whole blood and plasma by high-performance liquid chromatography with an internal standard]. Journal de pharmacie de Belgique. 1983 Nov; 38(6):299-303. doi: NULL. [PMID: 6674473]
  • T Aaes-Jørgensen, L Kirk, E Petersen, P Danneskiold-Samsøe, A Jørgensen. Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo. Psychopharmacology. 1983; 81(1):68-72. doi: 10.1007/bf00439276. [PMID: 6415733]
  • L Hochenegg. Clopentixol decanoate in the treatment of chronic alcoholism. Acta psychiatrica Belgica. 1981 Mar; 81(2):121-7. doi: . [PMID: 7293809]
  • T Aaes-Jørgensen. Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta psychiatrica Scandinavica. Supplementum. 1981; 294(?):64-9. doi: NULL. [PMID: 6951395]
  • T Aaes-Jørgensen, A Gravem, A Jørgensen. Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol. Acta psychiatrica Scandinavica. Supplementum. 1981; 294(?):70-7. doi: NULL. [PMID: 6951396]
  • S J Dencker, U Malm, A Jørgensen, K F Overø. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta psychiatrica Scandinavica. Supplementum. 1980; 279(?):55-63. doi: 10.1111/j.1600-0447.1980.tb07083.x. [PMID: 6931473]
  • K F Overø. A specific method for assay of drug levels in serum of patients treated with clopenthixol decanoate injections. Acta psychiatrica Scandinavica. Supplementum. 1980; 279(?):92-103. doi: 10.1111/j.1600-0447.1980.tb07086.x. [PMID: 6931474]
  • A Jrgensen, K F Overø. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta psychiatrica Scandinavica. Supplementum. 1980; 279(?):41-54. doi: 10.1111/j.1600-0447.1980.tb07082.x. [PMID: 6931472]
  • F Brambilla, G Penati, S Freni, S Bottinelli, C Maffei, V Maiella. Failure of pyridoxine to effect neuroleptic-induced hyperprolactinemia in psychotic patients. Journal of endocrinological investigation. 1979 Jul; 2(3):299-302. doi: 10.1007/bf03350421. [PMID: 43342]
  • E Gründig, J Weiss. [The influence of neuroleptic drugs on urinary excretion of non-protein nitrogen (author's transl)]. Arzneimittel-Forschung. 1976 Feb; 26(2):286-90. doi: . [PMID: 7281]
  • V Hansen, J Ravn, C Rud. Long-term treatment of psychiatric patients with clopenthixol: analysis of laboratory tests with a view to long-term therapy. Acta psychiatrica Scandinavica. 1974; 50(3):309-17. doi: 10.1111/j.1600-0447.1974.tb08216.x. [PMID: 4417465]
  • A R Khan. Some aspects of clopenthixol metabolism in rats and humans. Acta pharmacologica et toxicologica. 1969; 27(2):202-12. doi: 10.1111/j.1600-0773.1969.tb00507.x. [PMID: 5819574]
  • O H ARNOLD. A SYNDROME OF SIDE EFFECTS STUDIED WITH CLOPENTHIXOL. L'Encephale. 1964; 53(?):SUPPL:228-44. doi: NULL. [PMID: 14161538]